Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sparano

Showing results (341-350 of 560) with videos related to

Pageof 56
Sort By:
Cancer|April 1, 2021
Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trialGelareh Sadigh, Robert J Gray, Joseph A Sparano, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|April 1, 2019
Dietary calcium intake and adiposity in children and adolescents: Cross-sectional and longitudinal results from IDEFICS/I.Family cohortA Nappo, S Sparano, T Intemann, et al.
Journal of Biological Response Modifiers|December 1, 1990
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2bM Sznol, J W Mier, J Sparano, et al.
Journal of the Endocrine Society|November 18, 2022
Classic and Follicular Variant of Papillary Thyroid Microcarcinoma: 2 Different Phenotypes Beyond Tumor SizeClotilde Sparano, Mario Rotondi, Valentina Verdiani, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2020
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-upBhavana Pothuri, Allison L Brodsky, Joseph A Sparano, et al.
Cancer|June 22, 2010
Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapyMary Cianfrocca, Sandra Lee, Jamie Von Roenn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapyHenri Roché, Louise Yelle, Francesco Cognetti, et al.
Cancers|April 5, 2020
Validation of an Automated Quantitative Digital Pathology Approach for Scoring TMEM, a Prognostic Biomarker for MetastasisDavid Entenberg, Maja H Oktay, Timothy D'Alfonso, et al.
Breast Cancer Research and Treatment|March 4, 2014
Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103Kathryn J Ruddy, Anne O'Neill, Kathy D Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1997
Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanomaK Margolin, M Atkins, J Sparano, et al.
Pageof 56

Showing results (341-350 of 560) with videos related to

Sort By:
Pageof 56
Cancer|April 1, 2021
Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trialGelareh Sadigh, Robert J Gray, Joseph A Sparano, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|April 1, 2019
Dietary calcium intake and adiposity in children and adolescents: Cross-sectional and longitudinal results from IDEFICS/I.Family cohortA Nappo, S Sparano, T Intemann, et al.
Journal of Biological Response Modifiers|December 1, 1990
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2bM Sznol, J W Mier, J Sparano, et al.
Journal of the Endocrine Society|November 18, 2022
Classic and Follicular Variant of Papillary Thyroid Microcarcinoma: 2 Different Phenotypes Beyond Tumor SizeClotilde Sparano, Mario Rotondi, Valentina Verdiani, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2020
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-upBhavana Pothuri, Allison L Brodsky, Joseph A Sparano, et al.
Cancer|June 22, 2010
Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapyMary Cianfrocca, Sandra Lee, Jamie Von Roenn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapyHenri Roché, Louise Yelle, Francesco Cognetti, et al.
Cancers|April 5, 2020
Validation of an Automated Quantitative Digital Pathology Approach for Scoring TMEM, a Prognostic Biomarker for MetastasisDavid Entenberg, Maja H Oktay, Timothy D'Alfonso, et al.
Breast Cancer Research and Treatment|March 4, 2014
Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103Kathryn J Ruddy, Anne O'Neill, Kathy D Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1997
Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanomaK Margolin, M Atkins, J Sparano, et al.
Pageof 56